Literature DB >> 17848616

Determinants of PF4/heparin immunogenicity.

Shayela Suvarna1, Benjamin Espinasse, Rui Qi, Rauova Lubica, Mortimer Poncz, Douglas B Cines, Mark R Wiesner, Gowthami M Arepally.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an antibody-mediated disorder that occurs with variable frequency in patients exposed to heparin. HIT antibodies preferentially recognize large macromolecular complexes formed between PF4 and heparin over a narrow range of molar ratios, but the biophysical properties of complexes that initiate antibody production are unknown. To identify structural determinants underlying PF4/heparin immunogenicity, we characterized the in vitro interactions of murine PF4 (mPF4) and heparin with respect to light absorption, size, and surface charge (zeta potential). We show that PF4/heparin macromolecular assembly occurs through colloidal interactions, wherein heparin facilitates the growth of complexes through charge neutralization. The size of PF4/heparin macromolecules is governed by the molar ratios of the reactants. Maximal complex size occurs at molar ratios of PF4/heparin at which surface charge is neutral. When mice are immunized with complexes that differ in size and/or zeta potential, antibody formation varies inversely with heparin concentration and is most robust in animals immunized with complexes displaying a net positive zeta-potential. These studies suggest that the clinical heterogeneity in the HIT immune response may be due in part to requirements for specific biophysical parameters of the PF4/heparin complexes that occur in settings of intense platelet activation and PF4 release.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848616      PMCID: PMC2234783          DOI: 10.1182/blood-2007-08-105098

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  Light scattering as a diagnostic for protein crystal growth--a practical approach.

Authors:  W William Wilson
Journal:  J Struct Biol       Date:  2003-04       Impact factor: 2.867

2.  The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation.

Authors:  N A Mitchison
Journal:  Eur J Immunol       Date:  1971-01       Impact factor: 5.532

3.  Heparin-induced thrombocytopenia is rare in pregnancy.

Authors:  M B Fausett; M Vogtlander; R M Lee; M S Esplin; D W Branch; G M Rodgers; R M Silver
Journal:  Am J Obstet Gynecol       Date:  2001-07       Impact factor: 8.661

4.  Impact of the patient population on the risk for heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J A Sheppard; P Horsewood; P J Simpson; J C Moore; J G Kelton
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

5.  Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.

Authors:  M P Reilly; S M Taylor; N K Hartman; G M Arepally; B S Sachais; D B Cines; M Poncz; S E McKenzie
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.

Authors:  Zhong Q Li; Weiyi Liu; Kwang S Park; Brue S Sachais; Gowthani M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

7.  Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis.

Authors:  Susan I O'Shea; Jeffrey J Sands; Sybil A Nudo; Thomas L Ortel
Journal:  Am J Hematol       Date:  2002-01       Impact factor: 10.047

8.  Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery.

Authors:  John L Francis; George J Palmer; Rebecca Moroose; Alane Drexler
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

9.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

10.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

View more
  46 in total

1.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

2.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

3.  Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies.

Authors:  Mizuki Aimoto; Takahisa Yamane; Kazumasa Shiomoto; Chikahiko Sakamoto; Yasuhiro Nakashima; Hideo Koh; Takahiko Nakane; Yasunobu Takeoka; Asao Hirose; Mika Nakamae; Kiyoyuki Hagihara; Yoshiki Terada; Yoshitaka Nakao; Hirohisa Nakamae; Masayuki Hino; Shigeki Miyata
Journal:  Int J Hematol       Date:  2013-10       Impact factor: 2.490

4.  Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

Authors:  M V Joglekar; P M Quintana Diez; S Marcus; R Qi; B Espinasse; M R Wiesner; E Pempe; J Liu; D M Monroe; G M Arepally
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

Review 5.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography.

Authors:  Kido Nwe; Diane E Milenic; Geoffrey L Ray; Young-Seung Kim; Martin W Brechbiel
Journal:  Mol Pharm       Date:  2011-09-21       Impact factor: 4.939

7.  Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes.

Authors:  Michele P Lambert; Yuhuan Wang; Khalil H Bdeir; Yvonne Nguyen; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

Review 8.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

Review 9.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 10.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.